首頁 > 市場調查報告書 > 製藥

神經疾病

多發性硬化症治療藥物市場規模、佔有率和成長分析：按藥物類型、疾病類型、給藥途徑、分銷管道、最終用戶、患者類型和地區分類－2026-2033年產業預測

市場調查報告書

商品編碼

2054066

多發性硬化症治療藥物市場規模、佔有率和成長分析：按藥物類型、疾病類型、給藥途徑、分銷管道、最終用戶、患者類型和地區分類－2026-2033年產業預測

Multiple Sclerosis Therapeutics Market Size, Share, and Growth Analysis, By Drug Type, By Disease Type, By Route of Administration, By Distribution Channel, By End User, By Patient Type, By Region - Industry Forecast 2026-2033

出版日期: 2026年05月25日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球多發性硬化症治療市場價值為 282 億美元，預計從 2025 年的 298.4 億美元成長到 2033 年的 468.4 億美元，預測期（2026-2033 年）複合年成長率為 5.8%。

全球多發性硬化症 (MS) 治療市場的發展主要受疾病盛行率持續上升和創新治療方法研發的推動。診斷技術的進步正促使市場需求從症狀治療轉向疾病修正治療。該市場經歷了重大變革，從早期的注射療法發展到先進的口服調變器和高效能單株抗體。診斷技術的進步擴大了患者群體，刺激了對標靶高效治療方法和髓鞘再形成療法的投資。針對以往服務不足的患者群體，例如奧瑞珠單抗(Ocrelizumab )治療方法治療方法的推出，凸顯了減輕殘疾的潛力，也使其價格上漲成為合理之舉。此外，人工智慧 (AI) 透過改進標靶識別和臨床試驗設計，正在革新該領域的藥物研發，最終拓展了 MS 治療產品線，並創造了創新和市場成長的環境。

全球多發性硬化症治療市場的成長要素

全球多發性硬化症 (MS) 治療市場的發展主要得益於疾病修正治療的進步，這些療法改善了治療選擇和長期管理效果。這促使臨床醫師更早啟動治療，並提高了患者的藥物順從性。為此，製藥公司正加大對研發和商業化的投入，從而提高了各市場治療方法的可近性。隨著藥物分類和給藥方式的多樣化，保險公司和醫療保健系統也更加積極地促進治療的普及。此外，患者權益倡導組織透過宣傳活動，在推動市場需求方面發揮著至關重要的作用。這些因素共同推動了市場成長，豐富了產品線，並維持了投資活動，從而創造了穩健的市場環境。

全球多發性硬化症治療市場的限制因素

多發性硬化症先進療法的高昂費用給患者帶來了巨大的經濟負擔，也對保險報銷預算造成了壓力。這種情況迫使保險公司採取嚴格的資格標準並控制用藥管道，導致處方柔軟性受限。在醫療資源匱乏的地區，即使療效已被證實，這些用藥障礙也會減少接受治療的患者人數，並阻礙創新治療方法的推廣。此外，製藥公司還面臨談判挑戰，這可能導致產品上市延遲和開發過程複雜。而且，高昂的治療費用也會對患者的用藥依從性和後續治療產生負面影響，最終限制市場成長並降低商業性吸引力。

全球多發性硬化症治療市場趨勢

全球多發性硬化症 (MS) 治療市場正經歷著向基於生物標記的個人化治療的顯著轉變。這項轉變凸顯了新型診斷測試和分子譜分析的重要性，它們能夠根據每位患者的特定疾病機制量身定做治療方案。專科診所、診斷公司和製藥公司之間的合作至關重要，這有助於根據患者亞型調整治療方案，並提高標靶治療和聯合治療的療效。隨著支付者和醫療服務提供者越來越支持能夠帶來顯著功能性療效的分層治療路徑，精準醫療策略在各種醫療機構中的應用勢頭日益強勁。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

Biogen Inc.
Novartis AG
F. Hoffmann-La Roche Ltd.
Sanofi SA
Merck KGaA
Bristol Myers Squibb Company
Johnson & Johnson
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
AbbVie Inc.
Bayer AG
Takeda Pharmaceutical Company Limited
Amgen Inc.
Horizon Therapeutics plc
TG Therapeutics, Inc.
UCB SA
Eli Lilly and Company
Mylan NV
Genentech, Inc.
Acorda Therapeutics, Inc.

結論與建議

簡介目錄

Product Code: SQMIG35I2650

Global Multiple Sclerosis Therapeutics Market size was valued at USD 28.2 Billion in 2024 and is poised to grow from USD 29.84 Billion in 2025 to USD 46.84 Billion by 2033, growing at a CAGR of 5.8% during the forecast period (2026-2033).

The global market for multiple sclerosis (MS) therapeutics is driven by a persistent rise in disease prevalence and innovative treatment developments. As diagnostic techniques advance, demand is shifting from symptomatic relief to disease-modifying therapies. This market has evolved through significant transformations, from early injectable therapies to advanced oral modulators and high-efficacy monoclonal antibodies. Enhanced diagnostics have broadened the patient base, prompting investments in targeted, high-efficacy, and remyelination-focused treatments. The introduction of therapies like ocrelizumab for previously underserved populations highlights opportunities for reduced disability and justifies premium pricing. Furthermore, AI is revolutionizing drug discovery in this field by improving target identification and trial design, ultimately expanding the pipeline for MS therapies and fostering an environment of innovation and market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Sclerosis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiple Sclerosis Therapeutics Market Segments Analysis

Global multiple sclerosis therapeutics market is segmented by drug type, disease type, route of administration, distribution channel, end user, patient type and region. Based on drug type, the market is segmented into Immunomodulators, Immunosuppressants, Monoclonal Antibodies, Corticosteroids, Symptomatic Therapies and Others. Based on disease type, the market is segmented into Relapsing-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS) and Progressive-Relapsing Multiple Sclerosis (PRMS). Based on route of administration, the market is segmented into Oral, Injectable, Intravenous and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on end user, the market is segmented into Hospitals, Neurology Clinics, Specialty Centers, Home Care Settings and Others. Based on patient type, the market is segmented into Adult, Pediatric and Geriatric. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Multiple Sclerosis Therapeutics Market

The Global Multiple Sclerosis Therapeutics market is propelled by advancements in disease-modifying therapies that enhance treatment choices and long-term management outcomes. This leads clinicians to initiate treatment sooner and encourages patient adherence. In response, pharmaceutical companies are channeling investments into research and commercialization, thereby increasing the availability of therapies across various markets. With the emergence of diverse therapeutic classes and administration methods, payers and healthcare systems show a greater willingness to facilitate access. Furthermore, advocacy groups play a crucial role in driving demand through education. Collectively, these factors foster market growth, diversify product offerings, and sustain investment initiatives, resulting in a robust market landscape.

Restraints in the Global Multiple Sclerosis Therapeutics Market

The high costs associated with advanced therapies for multiple sclerosis create significant affordability challenges for patients and pressure reimbursement budgets. This situation leads payers to adopt strict coverage criteria and manage utilization, thereby limiting the flexibility of prescribing practices. In areas where healthcare funding is scarce, these access barriers diminish the number of patients receiving treatment and hinder the adoption of innovative therapies, despite their proven benefits. Additionally, manufacturers encounter negotiation challenges that can postpone market entry or complicate product placement. Furthermore, the perception of unaffordability can negatively affect patient adherence and continuity of care, ultimately restricting market growth and reducing commercial appeal.

Market Trends of the Global Multiple Sclerosis Therapeutics Market

The Global Multiple Sclerosis Therapeutics market is witnessing a significant trend towards personalized biomarker-guided therapies. This shift emphasizes the importance of emerging diagnostic assays and molecular profiling, which facilitate tailored treatment plans adjusting to the specific mechanisms of disease in individual patients. The collaboration among specialty clinics, diagnostics companies, and pharmaceutical firms has become crucial, as it helps align therapeutic developments with patient subtypes, enhancing the effectiveness of targeted agents and combination therapies. As payers and healthcare providers increasingly support stratified therapeutic pathways that yield meaningful functional outcomes, there is a growing momentum for the adoption of precision strategies across various care settings.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape
Value Chain Analysis
Case Studies
Technology Assessment
Customer & Buying Criteria Analysis
Pipeline Analysis
Disease Epidemiology

Global Multiple Sclerosis Therapeutics Market Size by Drug Type & CAGR (2026-2033)

Market Overview
Immunomodulators
Immunosuppressants
Monoclonal Antibodies
Corticosteroids
Symptomatic Therapies
Others

Global Multiple Sclerosis Therapeutics Market Size by Disease Type & CAGR (2026-2033)

Market Overview
Relapsing-Remitting Multiple Sclerosis (RRMS)
Secondary Progressive Multiple Sclerosis (SPMS)
Primary Progressive Multiple Sclerosis (PPMS)
Progressive-Relapsing Multiple Sclerosis (PRMS)

Global Multiple Sclerosis Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Injectable
Intravenous
Others

Global Multiple Sclerosis Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Global Multiple Sclerosis Therapeutics Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Neurology Clinics
Specialty Centers
Home Care Settings
Others

Global Multiple Sclerosis Therapeutics Market Size by Patient Type & CAGR (2026-2033)

Market Overview
Adult
Pediatric
Geriatric

Global Multiple Sclerosis Therapeutics Market Size & CAGR (2026-2033)

North America (Drug Type, Disease Type, Route of Administration, Distribution Channel, End User, Patient Type)
- US
- Canada
Europe (Drug Type, Disease Type, Route of Administration, Distribution Channel, End User, Patient Type)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Type, Disease Type, Route of Administration, Distribution Channel, End User, Patient Type)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Type, Disease Type, Route of Administration, Distribution Channel, End User, Patient Type)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Type, Disease Type, Route of Administration, Distribution Channel, End User, Patient Type)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Horizon Therapeutics plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TG Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acorda Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments